Cantor Fitzgerald Brokers Raise Earnings Estimates for BBIO

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Analysts at Cantor Fitzgerald upped their FY2025 EPS estimates for BridgeBio Pharma in a research report issued to clients and investors on Wednesday, April 30th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($3.93) for the year, up from their prior forecast of ($4.62). Cantor Fitzgerald has a "Overweight" rating and a $95.00 price objective on the stock. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share.

BBIO has been the topic of a number of other research reports. Piper Sandler boosted their price objective on shares of BridgeBio Pharma from $46.00 to $63.00 and gave the company an "overweight" rating in a research report on Wednesday, April 30th. HC Wainwright increased their price objective on BridgeBio Pharma from $49.00 to $53.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. Redburn Atlantic assumed coverage on BridgeBio Pharma in a research report on Monday, March 31st. They issued a "buy" rating and a $50.00 price objective on the stock. Scotiabank upped their target price on BridgeBio Pharma from $52.00 to $55.00 and gave the company a "sector outperform" rating in a report on Wednesday, April 30th. Finally, UBS Group lifted their price target on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $57.09.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO traded down $0.35 during mid-day trading on Friday, hitting $38.22. The stock had a trading volume of 2,121,331 shares, compared to its average volume of 2,351,581. The business has a 50 day moving average price of $34.06 and a two-hundred day moving average price of $30.91. BridgeBio Pharma has a 1 year low of $21.62 and a 1 year high of $39.54. The firm has a market cap of $7.26 billion, a P/E ratio of -13.41 and a beta of 1.15.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million for the quarter, compared to the consensus estimate of $57.14 million. BridgeBio Pharma's revenue was down 44.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.20) earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BBIO. Steward Partners Investment Advisory LLC lifted its stake in shares of BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after acquiring an additional 472 shares during the last quarter. GAMMA Investing LLC increased its stake in BridgeBio Pharma by 71.0% in the first quarter. GAMMA Investing LLC now owns 920 shares of the company's stock worth $32,000 after purchasing an additional 382 shares during the period. Itau Unibanco Holding S.A. bought a new stake in shares of BridgeBio Pharma during the fourth quarter worth $41,000. Sterling Capital Management LLC boosted its stake in shares of BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock valued at $49,000 after purchasing an additional 1,514 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in shares of BridgeBio Pharma in the fourth quarter worth about $109,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the completion of the sale, the insider now directly owns 19,260,971 shares of the company's stock, valued at approximately $634,841,604.16. This represents a 23.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Andrea Ellis sold 30,000 shares of the firm's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $34.05, for a total value of $1,021,500.00. Following the completion of the transaction, the director now directly owns 12,000 shares in the company, valued at $408,600. This trade represents a 71.43 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,309,191 shares of company stock worth $208,544,821. Corporate insiders own 24.66% of the company's stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.